Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00465985 · OUTCOME

Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part I.

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome · Source last updated 2017-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
pg/mL
Interval / dispersion
Standard Deviation
Time frame
until Week 8

Analysis population: Intention to treat (ITT) population.

Groups in this outcome

ACZ885

ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ACZ88535

Reported measurements

Source class 1
Values in pg/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
ACZ88519.04717.6609Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        17.6609
        value
        19.047
denoms
  1. counts
    1. group Id
      OG000
      value
      35
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.
    id
    OG000
    title
    ACZ885
param Type
MEAN
population Description
Intention to treat (ITT) population.
reporting Status
POSTED
time Frame
until Week 8
title
Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part I.
type
SECONDARY
unit Of Measure
pg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice